NephrologyOnline.net

Nephrology Xagena

XagenaNewsletter
Xagena Mappa
Medical Meeting
Dermabase.it

Search results for "Cabometyx"

Top-line results from the CABOSUN randomized phase 2 trial of Cabozantinib ( Cabometyx; Cometriq ) in patients with previously untreated advanced renal cell carcinoma ( RCC ) were announced. The tria ...


Cabozantinib ( Cabometyx ) is an oral multitargeted tyrosine kinase inhibitor ( TKI ) that potently inhibits MET and AXL, both associated with poor prognosis in renal cell carcinoma ( RCC ), next to v ...


Cabozantinib ( Cabometyx ) has improved progression-free survival ( PFS ), overall survival ( OS ) and objective response rate ( ORR ) compared with Everolimus in patients with advanced renal cell car ...